NCT00095004
Completed
Phase 3
A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild
ConditionsMigraine
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Migraine
- Sponsor
- Organon and Co
- Enrollment
- 167
- Primary Endpoint
- Percentage of patients who are pain free at 2 hours postdose
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Six month history of migraine; attacks typically mild when they begin with 1-4 migraine attacks per month.
Exclusion Criteria
- •Heart disease
- •High blood pressure
Outcomes
Primary Outcomes
Percentage of patients who are pain free at 2 hours postdose
Tolerability as measured by subjective adverse experience reporting
Secondary Outcomes
- Percentage of patients with 24 hour sustained pain freedom
- Percentage of patients requiring rescue medication between 2 & 24 hours
- Percentage of patients pain free at 30/45/60/90 minutes post dose
- Percentage of patients with associated symptoms at 2 hours
- Percentage of patients with functional disability at 2 hours
Similar Trials
Completed
Phase 3
Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)MigraineNCT00092963Organon and Co529
Recruiting
Phase 1
Safety and Efficacy of Early Administration of Dexamethasone in High-risk SepsisSepsisNCT05136560CHA University102
Not Yet Recruiting
Phase 4
RCT Study of Levosimendan Improving Prognosis of Cardiac ArrestHeart ArrestNCT05956431Peking University Third Hospital60
Recruiting
Phase 1
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)Advanced Solid TumorMetastatic Solid TumorNCT05898399Artios Pharma Ltd181
Completed
Phase 1
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT00657007Human Genome Sciences Inc.70